Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
- 1 May 2014
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 173 (2) , 290-294
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Medicines Company
- GlaxoSmithKline
- Otsuka America
- Roche
- Institut National de la Santé et de la Recherche Médicale (U698)
- Sanofi
- Servier
- AstraZeneca
- School of Medicine, New York University
- Eli Lilly and Company
- Pfizer
- Boehringer Ingelheim
- Medtronic
This publication has 14 references indexed in Scilit:
- Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world populationEuroIntervention, 2013
- Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trialEuroIntervention, 2013
- Bleeding Complications With Regional Adaptation of a Prolonged Bivalirudin Regimen for ST-Elevation Acute Myocardial InfarctionThe American Journal of Cardiology, 2012
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2012
- Prasugrel and bivalirudin for primary angioplasty: Early results on stent thrombosis and bleedingInternational Journal of Cardiology, 2011
- Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trialEuroIntervention, 2011
- Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatmentEuroIntervention, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trialThe Lancet, 2007
- Bivalirudin: A direct thrombin inhibitorClinical Therapeutics, 2002